"Designing Growth Strategies is in our DNA"

Insomnia Drugs Market Size, Share & Industry Analysis, By Drug Class (Dual Orexin Receptor Antagonists (DORAs), Z-drugs/Non-Benzodiazepine Hypnotics, Benzodiazepine Hypnotics, Melatonin Pathway Agents, and Others), By Disease Indication (Primary Chronic Insomnia Disorder, Comorbid Psychiatric Insomnia, Comorbid Neurologic/Pain-Related Insomnia, & Others), By Age Group (Adults and Pediatric), By Type (Branded and Generic), By Route of Administration (Oral and Others), By Distribution Channel (Hospital pharmacies, Drug Stores & Retail Pharmacies, & Others), and Regional Forecast, 2026-2034

Last Updated: June 01, 2026 | Format: PDF | Report ID: FBI116040

 

  • 2021-2034
  • 2025
  • 2021-2024
  • 190
Download Free Sample

    man icon
    Mail icon

Get 30-60 hrs Free Customization

Expand Regional and Country Coverage, Segments Analysis, Company Profiles, Competitive Benchmarking, and End-user Insights.

Growth Advisory Services
    How can we help you uncover new opportunities and scale faster?
Clients
3M
Toshiba
Fresenius
Johnson
Siemens
Abbot
Allergan
American Medical Association
Becton, Dickinson and Company
Bristol-Myers Squibb Company
Henry Schein
Mckesson
Mindray
National Institutes of Health (NIH)
Nihon Kohden
Olympus
Quest Diagnostics
Sanofi
Smith & Nephew
Straumann